Exec-Edge – Page 46 – ExecEdge

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib,...

Nanox.ARC Imaging System Granted Certification in EU

Nanox.ARC Imaging System Granted Certification in EU

By Karen Roman Medical tech company Nano-X Imaging Ltd. (Nasdaq: NNOX) said Nanox.ARC, its digital multi-source 3D tomosynthesis imaging system, received CE mark certification in the European market. Nanox.ARC also has FDA clearance for general use in the U.S. and...

On Q4 Gross Profit Soars 40%; Strong FY25 Outlook

On Q4 Gross Profit Soars 40%; Strong FY25 Outlook

By Karen Roman On Holding AG (NYSE: ONON) said fourth quarter adjusted diluted earnings per share increased to CHF 0.33 from CHF (0.05) the year prior, surpassing analysts’ expectations and raising its market price per share around 5%. Gross profit...

FIGS Q4 Revenue Up 5% to $151.8 million

FIGS Q4 Revenue Up 5% to $151.8 million

By Karen Roman Healthcare apparel brand FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue increased 4.8% to $151.8 million compared to the year prior, beating analysts’ expectations. Adjusted EBITDA was $21.1 million and adjusted EBITDA margin was 13.9%, compared...

Finding the Next Generation of Anesthesiologists

Finding the Next Generation of Anesthesiologists

By Exec Edge Editorial Staff Anesthesiologists are in short supply. Health systems around the nation are clamoring to find more of these vital physicians to meet ever-growing demand. The medical world is searching for solutions. Without anesthesia providers, there can...

Input your search keywords and press Enter.